Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

PYXS

Pyxis Oncology Inc

Apr 26 • 12:31PM ET

4.38

Dollar change +0.08
Percentage change 1.86	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC DFAT CANC DFAS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.86	Insider Own	20.40%	Shs Outstand	58.13M	Perf Week	5.29%
Market Cap	254.61M	Forward P/E	-	EPS next Y	-1.20	Insider Trans	0.00%	Shs Float	46.27M	Perf Month	4.29%
Income	-73.79M	PEG	-	EPS next Q	-0.24	Inst Own	29.05%	Short Float	4.77%	Perf Quarter	10.89%
Sales	0.00M	P/S	-	EPS this Y	50.87%	Inst Trans	-1.81%	Short Ratio	2.45	Perf Half Y	178.98%
Book/sh	2.81	P/B	1.56	EPS next Y	-31.92%	ROA	-38.32%	Short Interest	2.21M	Perf Year	56.99%
Cash/sh	2.08	P/C	2.11	EPS next 5Y	34.60%	ROE	-51.51%	52W Range	1.35 - 6.85	Perf YTD	143.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-118.72%	ROI	-50.61%	52W High	-36.06%	Beta	1.47
Dividend TTM	-	Quick Ratio	4.84	Sales past 5Y	0.00%	Gross Margin	-	52W Low	224.44%	ATR (14)	0.47
Dividend Ex-Date	-	Current Ratio	4.84	EPS Y/Y TTM	48.77%	Oper. Margin	0.00%	RSI (14)	43.92	Volatility	8.70% 10.56%
Employees	50	Debt/Eq	0.17	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.50
Option/Short	Yes / Yes	LT Debt/Eq	0.16	EPS Q/Q	66.25%	Payout	-	Rel Volume	0.16	Prev Close	4.30
Sales Surprise	-100.00%	EPS Surprise	28.39%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	902.61K	Price	4.38
SMA20	-10.18%	SMA50	-14.79%	SMA200	48.94%	Trades		Volume	71,176	Change	1.86%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-09-24	Initiated	BTIG Research	Buy	$8
Jan-23-24	Initiated	Leerink Partners	Outperform	$12
Sep-05-23	Initiated	RBC Capital Mkts	Outperform	$7
Nov-02-21	Initiated	Jefferies	Buy	$25
Nov-02-21	Initiated	Credit Suisse	Outperform	$19
Nov-02-21	Initiated	BofA Securities	Neutral	$16

Apr-12-24 09:55AM	Does Pyxis Oncology (PYXS) Have the Potential to Rally 61.29% as Wall Street Analysts Expect? (Zacks) -6.64%
Mar-28-24 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-27-24 07:30AM	Pyxis Oncology Obtains $8 Million Payment for the Sale of Royalty Rights (GlobeNewswire) +9.66%
Mar-26-24 12:00PM	All You Need to Know About Pyxis Oncology (PYXS) Rating Upgrade to Buy (Zacks)
Mar-21-24 01:53PM	PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023 (InvestorPlace) -8.66%
09:11AM	Loading…
09:11AM	Pyxis Oncology Inc (PYXS) Reports Encouraging Clinical Progress Amid Financial Challenges (GuruFocus.com)
07:30AM	Pyxis Oncology Provides Corporate Update and Reports Financial Results for Fourth Quarter and Full Year 2023 (GlobeNewswire)
Mar-13-24 08:00AM	Pyxis Oncology Expands Board of Directors with Appointment of Santhosh Palani, Ph.D., CFA (GlobeNewswire) -6.14%
Mar-07-24 04:30PM	Pyxis Oncology to Present at Leerink Global Biopharma Conference 2024 (GlobeNewswire)
Mar-05-24 04:45PM	Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting (GlobeNewswire)
Feb-27-24 08:00AM	Pyxis Oncology Announces $50 Million Private Placement (GlobeNewswire) +33.26%
Dec-29-23 04:30PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-23 07:00AM	Pyxis Oncology Announces Appointment of Ken Kobayashi, M.D., F.A.C.P as Chief Medical Officer (GlobeNewswire)
Nov-07-23 04:30PM	Pyxis Oncology Announces Initiatives to Prioritize Lead ADC Program; Reports Financial Results for Third-Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Oct-23-23 11:27AM	Inspiring the Next Generation of Entrepreneurs at the Diversity and Equity Accelerator through Learning for Startups (DEALS) Workshop (PR Newswire)
09:00AM	Loading…
Oct-13-23 09:00AM	New FDA Designations Accelerate Progress in Pancreatic Cancer Treatments: A Year in Review (PR Newswire)
Sep-27-23 09:18AM	Pyxis Oncology Announces Four Abstracts Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2023 (GlobeNewswire)
Sep-14-23 05:03PM	Insider Sell: President and CEO Lara Sullivan Sells 27,917 Shares of Pyxis Oncology Inc (GuruFocus.com)
Aug-31-23 04:01PM	Pyxis Oncology to Participate in Two Upcoming Investment Conferences (GlobeNewswire)
Aug-23-23 08:35AM	Pyxis Oncology Successfully Completes Acquisition of Apexigen (GlobeNewswire)
Aug-11-23 07:00AM	Pyxis Oncology Reports Financial Results for Second-Quarter 2023 and Provides Corporate Update (GlobeNewswire) +6.61%
Aug-01-23 04:01PM	Pyxis Oncology to Present at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jun-30-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-30-23 08:30AM	Pyxis Oncology Advances PYX-106 and PYX-201 Clinical Programs (GlobeNewswire)
May-24-23 06:45AM	Pyxis Oncology to Acquire Apexigen (GlobeNewswire) -10.46%
May-11-23 07:00AM	Pyxis Oncology Reports Financial Results for the First Quarter 2023 and Provides Corporate Update (GlobeNewswire)
Mar-31-23 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -33.17%
Mar-30-23 02:16PM	Pyxis Stock Is Up 170% This Week. How Much Higher Can It Go? (TipRanks) +32.16%
Mar-22-23 06:45AM	Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update (GlobeNewswire)
Mar-16-23 07:30AM	Pyxis Oncology Announces Dosing of First Subject in Phase 1 Trial of PYX-201, a Novel ADC for Solid Tumors (GlobeNewswire) +7.46%
08:00AM	Loading…
Feb-13-23 08:00AM	Pyxis Oncology to Participate in the Virtual 2023 SVB Securities Global Biopharma Conference (GlobeNewswire)
Dec-23-22 04:45PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
Dec-01-22 06:45AM	Pyxis Oncology Announces FDA Clearance of Two IND Applications (GlobeNewswire)
Nov-01-22 06:30AM	Pyxis Oncology Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Corporate Update (GlobeNewswire) -9.63%
Sep-30-22 05:00PM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-15-22 07:00AM	Pyxis Oncology Reports Financial Results for the Second Quarter Ended June 30, 2022 and Provides Pipeline Update (GlobeNewswire)
Jul-12-22 06:45AM	Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-28-22 06:35AM	Pyxis Oncology to Present at H.C. Wainwright Preclinical Cancer Drug Discovery Conference (GlobeNewswire)
Jun-21-22 10:40AM	Great news for Pyxis Oncology, Inc. (NASDAQ:PYXS): Insiders acquired stock in large numbers last year (Simply Wall St.)
May-19-22 06:35AM	Pyxis Oncology Announces Presentations at Upcoming Investor Conferences (GlobeNewswire)
May-13-22 08:03AM	Pyxis Oncology Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update (GlobeNewswire) -9.01%
May-07-22 10:34AM	Will Pyxis Oncology (NASDAQ:PYXS) Spend Its Cash Wisely? (Simply Wall St.)
Apr-27-22 06:35AM	Pyxis Oncology to Participate in Fireside Chat at BofA Securities 2022 Healthcare Conference (GlobeNewswire)
Apr-13-22 06:35AM	Pyxis Oncology Announces Leadership Changes (GlobeNewswire)
Apr-08-22 01:05PM	Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-29-22 11:00AM	Biosion licenses BSI-060T (anti-Siglec-15) to Pyxis Oncology (PR Newswire)
06:35AM	Pyxis Oncology Provides Corporate and Financial Update (GlobeNewswire)
Mar-22-22 06:35AM	Pyxis Oncology to Host Corporate Update Conference Call and Webcast on March 29, 2022 (GlobeNewswire) -8.04%
Jan-10-22 11:17AM	Quite a few insiders invested in Pyxis Oncology, Inc. (NASDAQ:PYXS) last year which is positive news for shareholders (Simply Wall St.)
Dec-15-21 08:00AM	Pyxis to be Added to Russell 2000® Index (GlobeNewswire)
Dec-09-21 08:30AM	Pyxis Oncology Appoints Martina Molsbergen as Interim Chief Business Officer (GlobeNewswire)
Nov-15-21 07:15AM	Pyxis Reports Financial Results for the Third Quarter of 2021 and Provides Business Update (GlobeNewswire)
Nov-10-21 08:00AM	Pyxis Oncology to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-08-21 03:31PM	Pyxis Oncology well positioned to advance its work against cancer amid public debut: CEO (Yahoo Finance Video)
Oct-07-21 10:24PM	Pyxis Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Connealy Pamela Ann	CFO and COO	Sep 28 '23	Buy	1.87	8,000	14,960	818,532	Sep 28 04:32 PM
Connealy Pamela Ann	CFO and COO	Sep 27 '23	Buy	1.85	6,426	11,868	810,532	Sep 27 06:36 PM
Wadhane Jitendra	Chief Accounting Officer	Sep 27 '23	Buy	1.87	2,500	4,675	226,937	Sep 27 06:37 PM
Connealy Pamela Ann	CFO and COO	Sep 25 '23	Buy	1.67	12,000	20,044	804,106	Sep 25 05:04 PM
Wadhane Jitendra	Chief Accounting Officer	Sep 25 '23	Buy	1.77	5,000	8,850	224,437	Sep 25 05:05 PM
Connealy Pamela Ann	CFO and COO	Sep 22 '23	Buy	1.74	5,000	8,695	792,106	Sep 22 07:34 PM
Wadhane Jitendra	Chief Accounting Officer	Sep 22 '23	Buy	1.74	2,500	4,349	219,437	Sep 22 07:35 PM
Sullivan Lara	President and CEO	Sep 18 '23	Sale	2.10	8,541	17,936	2,403,882	Sep 18 07:03 PM
Sullivan Lara	President and CEO	Sep 14 '23	Sale	2.25	100	225	2,412,423	Sep 18 07:03 PM
Sullivan Lara	President and CEO	Sep 13 '23	Sale	2.27	3,000	6,816	2,597,265	Sep 13 08:16 PM
Sullivan Lara	President and CEO	Sep 12 '23	Sale	2.25	4,917	11,071	2,600,265	Sep 13 08:16 PM
Sullivan Lara	President and CEO	Sep 11 '23	Sale	2.27	20,000	45,414	2,605,182	Sep 13 08:16 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PYXS

Pyxis Oncology Inc

Upgrade your FINVIZ experience